Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Purity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Purity. Displaying page 1 of 1.
    EudraCT Number: 2009-015086-31 Sponsor Protocol Number: Ten03 Start Date*: 2010-03-16
    Sponsor Name:Bio Products Laboratory Limited
    Full Title: Ten03: A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL’s High Purity Factor X in the treatment of the Factor X Deficient Subjects Undergoing Surgery
    Medical condition: Factor X Deficiency
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000913-30 Sponsor Protocol Number: Nath1/2008 Start Date*: 2008-10-13
    Sponsor Name:NATHURA SRL
    Full Title: A symbiotic for the treatment of functional constipation
    Medical condition: Functional crhonic constipation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063582 Constipation chronic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003421-28 Sponsor Protocol Number: TUD-HINKL1-059 Start Date*: 2014-07-10
    Sponsor Name:Technische Universität Dreden
    Full Title: Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia
    Medical condition: Newly diagnosed high-risk AML other than acute promyelocytic leukemia, ≥20% blasts
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001890-56 Sponsor Protocol Number: COVID-Γ Start Date*: 2020-06-10
    Sponsor Name:Universidad Católica de Murcia (UCAM)
    Full Title: Double-blind randomized placebo-controlled clinical trial to evaluate the efficacy and safety of the use of intravenous gammaglobulins in the treatment of patients with COVID-19
    Medical condition: Patients with severe symptoms of COVID-19, a disease caused by infection with the SARS-CoV-2 virus.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003772-23 Sponsor Protocol Number: ZLB05_006CR Start Date*: 2015-04-14
    Sponsor Name:CSL Behring AG
    Full Title: A Multicenter Extension Study on the Safety and Efficacy of IgPro10 in Patients With Primary Immunodeficiency (PID)
    Medical condition: Primary Immune Deficiency (Common Variable Immunodeficiency and X-linked agammaglobulinemia)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10064859 Primary immunodeficiency syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003093-98 Sponsor Protocol Number: Ten02 Start Date*: 2015-02-24
    Sponsor Name:Bio Products Laboratory Limited
    Full Title: A Phase III Open, Multicentre Study to Confirm the Safety, Pharmacokinetics and Efficacy of BPL’s High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of...
    Medical condition: Factor X Deficiency
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011145-18 Sponsor Protocol Number: TEN01 Start Date*: 2009-11-02
    Sponsor Name:Bio Products Laboratory Ltd
    Full Title: A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency
    Medical condition: Factor X deficiency
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10052474 Factor X deficiency PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003445-37 Sponsor Protocol Number: ELPIDA-ALLOCART-01 Start Date*: 2021-09-30
    Sponsor Name:Aghia Sophia Children’s Hospital
    Full Title: A Phase 2 Study of the Efficacy and Safety of a Dose of Donor-Derived CD19-targeted CAR T cells for children and young adults (up to 39 years old) with recurrent or persistent CD19 (+) Acute Leukem...
    Medical condition: Relapsed b Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063620 Acute lymphocytic leukaemia recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-017672-24 Sponsor Protocol Number: IgPro10_3001 Start Date*: 2010-09-13
    Sponsor Name:CSL Behring GmbH
    Full Title: A single-arm study to demonstrate the efficacy and safety of Privigen in the treatment of subjects with chronic inflammatory demyelinating polyneuropathy (CIDP)
    Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10061811 Demyelinating polyneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2006-000664-85 Sponsor Protocol Number: 8VWF03 Start Date*: 2006-12-19
    Sponsor Name:Bio Products Laboratory
    Full Title: An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and von Willebrand Factor Concentrate, in Patients with von Willebrand Di...
    Medical condition: von Willebrand disease
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000663-28 Sponsor Protocol Number: 8VWF01 Start Date*: Information not available in EudraCT
    Sponsor Name:Bio Products Laboratory
    Full Title: An open multi-centre study in patients with von Willebrand Disease to investigate the pharmacokinetics, efficacy and safety of Optivate, a high purity, dual inactivated Factor VIII and Von Willebra...
    Medical condition: von Willebrands Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047715 Von Willebrand's disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000263-27 Sponsor Protocol Number: IgPro10_4001 Start Date*: 2011-07-22
    Sponsor Name:CSL Behring LLC
    Full Title: An open-label, prospective, multicenter study to investigate the specificity of in vivo antibody binding to red blood cells in subjects with chronic immune thrombocytopenic purpura (ITP) treated wi...
    Medical condition: Chronic immune thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-023830-22 Sponsor Protocol Number: AAG-G-H-1102 Start Date*: 2012-05-23
    Sponsor Name:TETEC AG
    Full Title: NDisc Study: A Prospective Randomized Multicentre Phase I / II Clinical Trial to Evaluate Safety and Efficacy of NOVOCART® Disc plus Autologous Disc Chondrocyte Transplantation (ADCT) in the Treatm...
    Medical condition: The subject has a disc herniation with back and /or leg pain (radicular pain) and an identification for sequestrectomy according to the guidelines of DGNC and DGOOC.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10022634 Intervertebral disc disorders LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001514-34 Sponsor Protocol Number: ILNK15-01 Start Date*: 2012-04-03
    Sponsor Name:Leiden University Medical Center
    Full Title: Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility study
    Medical condition: Children with high-risk and recurrent acute leukemia are eligible for allogeneic hematopoietic stem cell transplantation (HSCT). However, leukemia relapse and viral infections after HSCT remain mai...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10023685 LAK cell therapy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001410-33 Sponsor Protocol Number: UZB-VUB-11-01 Start Date*: 2016-03-10
    Sponsor Name:UZ BRUSSEL
    Full Title: Randomized phase II clinical trial on mRNA electroporated autologous dendritic cells for stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment o...
    Medical condition: stage III/IV melanoma in patients who are free from measurable tumor lesions following the local treatment of macro metastases
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003450-92 Sponsor Protocol Number: IG1005 Start Date*: 2013-11-23
    Sponsor Name:Instituto Grifols S.A.
    Full Title: EVALUATION OF THE PHARMACOKINETIC PROFILE, CLINICAL EFFICACY AND SAFETY OF THE VON WILLEBRAND FACTOR CONTAINED IN FANHDI® (DOUBLE-INACTIVATED HUMAN ANTI-HEMOPHILIC FACTOR) IN PEDIATRIC PATIENTS WIT...
    Medical condition: Severe von Willebrand disease including types I, II, and III with VWF:RCof <15-20%
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10068986 Von Willebrand's factor activity decreased PT
    14.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    14.1 10010331 - Congenital, familial and genetic disorders 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021781-29 Sponsor Protocol Number: BAY81-8973/13400 Start Date*: 2011-07-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter Phase III uncontrolled open-label trial to evaluate safety and efficacy of BAY 81-8973 in children with severe haemophilia A under prophylaxis therapy
    Medical condition: Severe Hemophilia-A (< 1% FVIII:C)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10010331 - Congenital, familial and genetic disorders 10060612 Hemophilia A LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: HU (Completed) LT (Completed) SE (Completed) DK (Completed) IE (Completed) LV (Completed) BG (Completed) IT (Completed) PL (Completed) AT (Completed) ES (Completed) GB (Completed) NO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 11 00:14:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA